On October 8, 2026, RoboSense (02498.HK) edged lower in afternoon trading. As of 14:16, it quoted HK$15.75, down 1.99%.
SMIC (00981.HK) fell 5.17% to HKD 57.750. Applied Materials and Intel will jointly develop AI chip packaging; SIGURD of Taiwan, China posted record Q3.
UBTECH ROBOTICS (09880.HK) fell 4.64% to HKD 70.950. It signed a logistics robot deal with FAW-Volkswagen; Nvidia may invest another USD 1bn in Figure.
On 5 October 2026, CSPC PHARMA (01093.HK) said it will present 8 clinical trial updates at the ESMO Congress 2026 in Madrid, two of them as LBAs.
On 5 October 2026, SIHUAN PHARM (00460.HK) said five new specifications of its skin booster Dongyan were approved for launch in China by the NMPA.
On 2 October 2026, Ascletis Pharma Inc. (01672.HK) announced that key preclinical data for ASC36_35FDC were presented at the 62nd Annual Meeting of the European Association for the Study of Diabete.
On 2 October 2026, QYUNS-B (02509.HK) said the China Phase III data of Oturkibart in prurigo nodularis were presented at EADV 2026 and met the primary endpoint.
On 1 October 2026, VALA (02051.HK) said its third model vala kcar began delivery in late September, with 420 automobiles delivered in the third quarter.
On 30 September 2026, CSPC PHARMA reported positive Phase III results for its GLP-1 receptor agonist Efmedaglutide Alfa Injection in type 2 diabetes.
On 30 September 2026, INSILICO (03696.HK) named ISM1354 a potentially best-in-class GIPR antagonist as preclinical candidate for obesity and type 2 diabetes.
On September 30, 2026, XPENG-W (09868.HK) edged higher. As of 14:06, it traded at HK$37.74, up 0.64%.
On 29 September 2026, IDT INT'L (00167.HK) agreed to buy 40 units of AI servers for RMB 127.11 million from Hangzhou Dongnan Jitong, a discloseable transaction.
On 29 September 2026, LIVZON PHARMA (01513.HK) said its Leuprorelin Acetate Microspheres for Injection 11.25mg was approved for marketing in China.
On 29 September 2026, CSPC PHARMA (01093.HK) said the Phase Ib trial of JMT206 Injection for weight management in overweight or obese adults began in China.
On September 29, 2026, BIDU-W (09888.HK) weakened. As of 14:09, it quoted HK$84.40 per share, down 1.34%.
On 28 September 2026, CSPC PHARMA (01093.HK) said SYS6077 injection has received NMPA approval for clinical trials in China for advanced malignant tumors.
